- Home
- ACLX vs PRCT Comparison
ACLX vs PRCT Comparison
Compare ACLX & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACLX | PRCT |
|---|---|---|
| Founded | 2015 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 2.0B |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ACLX | PRCT |
|---|---|---|
| Price | $63.73 | $31.21 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 9 |
| Target Price | ★ $115.71 | $51.13 |
| AVG Volume (30 Days) | 1.2M | ★ 1.4M |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $35,898,000.00 | ★ $299,907,000.00 |
| Revenue This Year | N/A | $48.30 |
| Revenue Next Year | $293.08 | $29.44 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 50.07 |
| 52 Week Low | $47.86 | $27.80 |
| 52 Week High | $94.07 | $89.49 |
Technical Indicators
Market Signals| Indicator | ACLX | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 34.06 | 41.67 |
| Support Level | $63.48 | $31.78 |
| Resistance Level | $66.79 | $32.94 |
| Average True Range (ATR) | 2.31 | 1.44 |
| MACD | 0.25 | -0.38 |
| Stochastic Oscillator | 10.64 | 3.59 |
Price Performance
Historical ComparisonAbout ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.